The TRUTAKNA launch is the primary catalyst, not quarterly financials. Watch for ORIGIN 3 final efficacy data in Q3 2026 and sBLA submission in Q4 2026, which could drive full approval. The accelerating cash burn (doubled in H1 2026 vs H1 2025) makes the upcoming data readouts and potential financing events critical for near-term price action.
Drug in focus
VERA drug pipeline →TRUTAKNA
▲ Bullish Named in this press release- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
- Next catalyst
- None dated
What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 11 $30.29entry
- T+1 · 3mo ago −0.99%α −1.24% · $29.99
- T+5 · 3mo ago +6.57%α +6.97% · $32.28
- T+20 · 2mo ago +11.52%α +12.58% · $33.78
- T+60 · 13d ago +5.55%α +6.03% · $31.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vera Therapeutics reported Q2 2026 net loss of $109.5M (-$1.52 EPS), wider than the $76.5M loss in Q2 2025 and a miss vs consensus (-$1.69 EPS implied by the Q1 context miss pattern vs -$1.59 consensus). The key positive is the FDA accelerated approval of TRUTAKNA and its early commercial launch in IgAN, offset by a cash burn of $206.8M in H1 2026 and no revenue yet.
Key Financial Metrics
Key Facts
- FDA accelerated approval of TRUTAKNA (atacicept-vymj) for IgAN, first BAFF/APRIL inhibitor approved
- U.S. commercial launch underway; early reception described as encouraging
- Q2 2026 net loss of $109.5M vs $76.5M in Q2 2025; operating expenses $112.5M vs $80.1M
- Net cash used in operating activities H1 2026: $206.8M vs $109.2M in H1 2025
- Cash and securities $499.2M at June 30, 2026 plus up to $425M debt facility
- Final ORIGIN 3 efficacy data expected Q3 2026; sBLA submission for full approval expected Q4 2026
- Potential full approval of TRUTAKNA in IgAN expected in 2027
Financial Impact
Q2 2026 net loss $109.5M (-$1.52 EPS) vs consensus miss pattern; cash burn of $206.8M in H1; no product revenue yet
Risk Factors
- Accelerating cash burn $206.8M in H1 2026 may necessitate dilutive financing before cash flow breakeven
- Full approval still contingent on ORIGIN 3 confirmatory trial; failure would limit revenue opportunity
- Commercial launch execution risk despite experienced team; no product revenue guidance provided
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342203 |
Track record
25 reports on VERA
13 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 14 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers